S.C.P.C — Investor Presentation 2021

Apr 21, 2021

==> picture [443 x 234] intentionally omitted <==

Standard Chem & Pharm CO., LTD. Stock symbol: 1720

2021 Investor Conference 12.04.2021

==> picture [320 x 85] intentionally omitted <==

Agenda

==> picture [98 x 91] intentionally omitted <==

 Introduction of Standard Group

 2020 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

1

© 2021 SCPC, Ltd

免責聲明Safe Harbor Notice

==> picture [98 x 91] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事 件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必 然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何 事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

2

© 2021 SCPC, Ltd

==> picture [261 x 540] intentionally omitted <==

----- Start of picture text -----

© 2021 SCPC, Ltd
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2020 Operating Results

 Further Operation Strategy  Corporate Social Responsibility (CSR)

3

==> picture [919 x 483] intentionally omitted <==

----- Start of picture text -----

SCP and Related/Affiliated Companies
Upstream Manufacture Downstream
Syn-Tech (1982; 2005 SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC) ) 1995 listed stock)
Western
medicine
Your Chance
Syngen(1999; 2016 OTC ) Souriree(1997)
(2013 Re-investment)
Multipower
Syngen(1999)
(2012 Re-investment)
Healthcare
nutrition
Sun-you(1994) Advpharma (1999)
Medical-
Syngen (1999)
devices
Q
Inforight(2000)
Gene chip Advpharma (1999) Software/Hardware
service support
4
----- End of picture text -----

==> picture [123 x 17] intentionally omitted <==

----- Start of picture text -----

© 2021 SCPC, Ltd
----- End of picture text -----

International Accreditation

==> picture [698 x 46] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [47 x 50] intentionally omitted <==

==> picture [32 x 42] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [56 x 35] intentionally omitted <==

==> picture [51 x 28] intentionally omitted <==

The first TW company to pass US FDA SCP passed subsequent US FDA inspection in 2000 cGMP inspections without 483

==> picture [32 x 42] intentionally omitted <==

SCP received JP PMDA’s FDF Plant and API Plant passed “Certificate of Foreign Drug PMDA GMP Audit in 2018 Manufacturer” in 2008

==> picture [56 x 34] intentionally omitted <==

==> picture [64 x 41] intentionally omitted <==

2009

==> picture [54 x 37] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [50 x 39] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA 2012 SCP passed K-FDA inspection

==> picture [54 x 40] intentionally omitted <==

==> picture [54 x 38] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

45
----- End of picture text -----

© 2021 SCPC, Ltd

Agenda

==> picture [98 x 91] intentionally omitted <==

 Introduction of Standard Group

 2020 Operating Results

 Further Operation Strategy  Corporate Social Responsibility (CSR)

6

© 2021 SCPC, Ltd

54 Years of Continuous Profit

==> picture [785 x 407] intentionally omitted <==

----- Start of picture text -----

Profit Stock Dividend Cash Dividend EPS
600,000 3.50
2.93
3.00
500,000
2.50
400,000 2.09 2.15 2.09 2.09 2.11
2.03
1.95
1.88 1.90
1.81 2.00
1.77
1.73
1.61
300,000
1.47
1.35 1.50
200,000
1.00
1.20 1.50 1.25 1.20 1.60 0.50 1.00 1.20 1.00 1.50 1.50 1.60 1.50 1.50
2.50
100,000
0.50
0.70
0.30 0.30
0 0.00
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q 7

© 2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

Consolidated Income Statement

Items	2020	2019	Diff.	Annual changes(%)	Q
(Unless otherwise specified, expressed in thousands of New Taiwan Dollars)
Operatingrevenue	4,305,400	3,937,129	368,271	9%
Gross profit	1,919,838	1,709,131	210,707	12%
Gross profit rate	44.59%	43.41%		+1.2pct
Operatingexpenses	1,213,251	1,193,287	19,964	2%
Operatingprofit	706,587	515,844	190,743	37%
Non-operatingincome and expenses	66,340	69,966	(3,626)	(5%)
Profit before income tax	772,927	585,810	187,117	32%
Profit for theyear	625,560	470,433	155,127	33%
Profit attributable to owners of the parent	524,172	376,482	147,690	39%
EPS(NTD)	2.93	2.11	0.82	39%

==> picture [64 x 64] intentionally omitted <==

8

© 2021 SCPC, Ltd

Global Revenue Ratio of Past 5 Years (Consolidated)

International Domestic

21 SCPC, Ltd 2016 2017 2018 2019 2020 17.5% 19.4% 19.2% 17.2% 17.9% 82.5% 80.6% 80.8% 82.8% 82.1% Expressed in thousands of NTD 2020 2019 2018 2017 2016 Export revenue 768,863 678,464 686,077 745,705 644,528 Total operating revenue 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801	21 SCPC, Ltd 2016 2017 2018 2019 2020 17.5% 19.4% 19.2% 17.2% 17.9% 82.5% 80.6% 80.8% 82.8% 82.1% Expressed in thousands of NTD 2020 2019 2018 2017 2016 Export revenue 768,863 678,464 686,077 745,705 644,528 Total operating revenue 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801	21 SCPC, Ltd 2016 2017 2018 2019 2020 17.5% 19.4% 19.2% 17.2% 17.9% 82.5% 80.6% 80.8% 82.8% 82.1% Expressed in thousands of NTD 2020 2019 2018 2017 2016 Export revenue 768,863 678,464 686,077 745,705 644,528 Total operating revenue 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801	21 SCPC, Ltd 2016 2017 2018 2019 2020 17.5% 19.4% 19.2% 17.2% 17.9% 82.5% 80.6% 80.8% 82.8% 82.1% Expressed in thousands of NTD 2020 2019 2018 2017 2016 Export revenue 768,863 678,464 686,077 745,705 644,528 Total operating revenue 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801	21 SCPC, Ltd 2016 2017 2018 2019 2020 17.5% 19.4% 19.2% 17.2% 17.9% 82.5% 80.6% 80.8% 82.8% 82.1% Expressed in thousands of NTD 2020 2019 2018 2017 2016 Export revenue 768,863 678,464 686,077 745,705 644,528 Total operating revenue 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801	21 SCPC, Ltd 2016 2017 2018 2019 2020 17.5% 19.4% 19.2% 17.2% 17.9% 82.5% 80.6% 80.8% 82.8% 82.1% Expressed in thousands of NTD 2020 2019 2018 2017 2016 Export revenue 768,863 678,464 686,077 745,705 644,528 Total operating revenue 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801
Expressed in thousands of NTD	2020	2019	2018	2017	2016
Export revenue	768,863	678,464	686,077	745,705	644,528
Total operating revenue	4,305,400	3,937,129	3,573,093	3,848,684	3,673,801
21 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

9
----- End of picture text -----

© 2021 SCPC, Ltd

Global Revenue Ratio Comparison (Consolidated)

Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)	Global Revenue Ratio Comparison (Consolidated)
2021 SCPC, Ltd 0 50,000 100,000 150,000 200,000 250,000 Southeast Asia China Other Asia Japan Other Americas Europe USA Africa Others 2020 2019 Expressed in thousands of NTD Southeast Asia China Other Asia Japan Other Americas Europe USA Africa Others 2020 248,996 225,978 96,179 51,289 43,263 40,945 32,724 29,341 149 2019 248,552 125,597 120,463 28,005 41,599 40,634 38,128 33,500 1,985 32% 37% 29% 19% 13% 18% 7% 4% 6% 6% 5% 6% 4% 6% 4%5%
Expressed in thousands of NTD	Southeast Asia	China	Other Asia	Japan	Other Americas	Europe	USA	Africa	Others
2020	248,996	225,978	96,179	51,289	43,263	40,945	32,724	29,341	149
2019	248,552	125,597	120,463	28,005	41,599	40,634	38,128	33,500	1,985
2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

10
----- End of picture text -----

© 2021 SCPC, Ltd

Peer Comparison & Ranking: Revenue Growth Amount & Growth Rate (Consolidated)

-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000	-300,000 -200,000 -100,000 0 100,000 200,000 300,000 400,000
Expressed in thousands of NTD		SCPC	SYN MOSA	BORA	CCPC	TBC	GBL	JCP	SIN PHAR	NANG KUANG	CHI SHENG	YSP	TTY
Growth amount		368,271	358,320	270,354	211,356	24,415	6,967	(1,324)	(6,137)	(7,432)	(43,597)	(106,867)	(244,472)
Growth rate%		9.4%	13.4%	17.7%	2.7%	0.5%	1.5%	(0.3%)	(0.3%)	(0.4%)	(4.3%)	(1.3%)	(5.5%)
2021 SCPC, Ltd

© 2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

11
----- End of picture text -----

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Expressed in thousands of NTD

									Revenue 4,305,400	Revenue 4,305,400
	1,200,000		Revenue 3,673,801		Revenue 3,848,684 Growth rate5%	Revenue 3,573,093 Growth rate-7%	Revenue 3,937,129 Growth rate10%		Growth rate9%
	1,000,000
	800,000
	600,000
	400,000
	200,000
		0
		Q1	2016 859,024		2017 909,933	2018 763,261	2019 846,177		2020 1,034,417
		Q2	940,238		976,177	897,693	1,010,837		1,108,059
		Q3	919,663		1,056,753	913,353	1,048,886		1,045,351
		Q4	954,876		905,821	998,786	1,031,229		1,117,573
	SCPC, Ltd

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

11
----- End of picture text -----

© 2021 SCPC, Ltd

Consolidated Balance Sheet

Items	2020	2020	2019	2019	Diff.	Annual changes(%)
(Expressed in thousands of NTD)	Amount	%	Amount	%
Cash and cash equivalents	1,036,183	15%	1,471,902	21%	(435,719)	(30%)
Accounts receivable	967,254	14%	911,021	13%	56,233	6%
Inventories	893,512	13%	914,629	13%	(21,117)	(2%)
Investments	806,055	11%	755,474	11%	50,581	7%
Property,plant and equipment	2,125,207	30%	2,116,644	31%	8,563	0%
Others	1,221,236	17%	758,334	11%	462,902	61%
Total Assets	**7,049,447 **	100%	**6,928,004 **	100%	121,443	2%
Current Liabilities	1,650,616	23%	1,813,056	26%	(162,440)	(9%)
Non-current Liabilities	492,996	7%	468,527	7%	24,469	5%
Total liabilities	2,143,612	30%	2,281,583	33%	(137,971)	(6%)
Total shareholder’s equity	4,905,835	70%	4,646,421	67%	259,414	6%
Debt Ratio(Abilities/Assets)		30%		33%		(3.0pct)
2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

12

© 2021 SCPC, Ltd

Consolidated Cash Flows

Items	2020	2019
(Expressed in thousands of NTD)
Cash at beginning ofyear	1,471,902	1,254,061
Cash flows from operatingactivities	922,580	652,447
Acquisition ofproperty, plant and equipment	(307,126)	(102,245)
Cash dividends	(268,044)	(268,044)
Short-term borrowings	(299,000)	130,000
Investment and others	(484,129)	(194,317)
Cash at end ofyear	1,036,183	1,471,902
Free cash flow* (Cash flows from operating activities-Acquisition of property, plant and equipment)	615,454	550,202

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [64 x 64] intentionally omitted <==

13

© 2021 SCPC, Ltd

Agenda

==> picture [98 x 91] intentionally omitted <==

 Introduction of Standard Group

 2020 Operating Results

 Further Operation Strategy  Corporate Social Responsibility (CSR)

14

© 2021 SCPC, Ltd

Q

Future Milestone

==> picture [290 x 122] intentionally omitted <==

==> picture [96 x 123] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics

==> picture [356 x 123] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

15

© 2021 SCPC, Ltd

SCP – Major International Businesses of the Past 2 Years

==> picture [59 x 58] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

==> picture [73 x 57] intentionally omitted <==

Japan

China

Taiwan

• Continues export of antibiotic injection.

• Bronchiolitis drug, non-

• Prompt delivery of drugs

​steroid anti-inflammatory drugs are persistently

during COVID-19 due to

• Generic Quality Consistency Evaluation(GQCE) ： 3 cases were closed; 5 ongoing

well-managed production

delivery

and sales coordination.

• SCP, Syn-Tech and

applications • Self-developed generic drug: two were submitted for review

Syngen’s turnover and gross profit have hit a historic high.

==> picture [43 x 39] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [31 x 27] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

16

© 2021 SCPC, Ltd

Q

Revenue Growth Strategy - Taiwan

• Taiwan as Base of Operations for Global R&D and Pharmaceutical Manufacturing

• Export sales growth in 2021

• International marketing to create an optimization market.

• Concrete work-division enhances international competitiveness

• Group resource integration

• Transfer the API department to Syn-Tech

• Production-marketing coordination

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

• Availability of raw material supply in order to prompt delivery during COVID-19.

• SCP, Syn-Tech and Syngen’s turnover and gross profit have hit a historic high.

17

© 2021 SCPC, Ltd

Concrete Work-Division Enhances International Competitiveness

• In 2014, sold nutritional biochemistry department to Syngen

• .

• In 2021, transfer the API department to Syn-Tech in October 1[st]

Firm	Type	Mainproduct
SCP	Pharmaceutical	Western medicine
Syngen	Nutritional biochemistry、 API	Nutritional biochemistryOEM, Fermentation skills
Syn-Tech	API	API

• SCP is the largest shareholder of Syn-Tech and the shareholding percentage has increased from 10.61% to 22.32%.

• API export is approximately 90% are produced by SCP’s synthesis department and Syn-Tech.

• Division specialized field, resources and vertical Integration to expend at home and abroad marketplace.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

© 2021 SCPC, Ltd

Revenue Growth Strate - China gy

==> picture [80 x 81] intentionally omitted <==

Competitiveness

==> picture [77 x 61] intentionally omitted <==

• SCP has successful experience with U.S. and Japan regulatory dossiers

NMPA review of importation

 SCP to continue to specialize expertise in BE design and execution

Medium-term targets

NMPA Consistency Evaluation

 Self-developed products submission

• 8 contracts signed, 3 cases were closed, and 5 ongoing cases

• Enhance profit sharing revenue

Cooperation

Strategy

 Tech-transfer

• Emphasize export and tech transfer simultaneously.

• Increase the number of cooperative projects and pharmaceutical companies

 License cooperation

• Co-development

• Profit-sharing Partnerships

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

19
----- End of picture text -----

© 2021 SCPC, Ltd

The Current Status of China- Market Trends

China Pharmaceutical Brand Drugs Firms Transfer from centralized Stay at market trends of API and procurement to external market focus on high techniques threshold • Approximately 80% is centralized • As centralized procurement status, procurement market the majority firms tend to develop • Brand drug prices are high and so their own API to decrease the price. only minority brand drug can win the Lower gross margin, but bid in centralized procurement. compensated with high sale volume. • Brand drug will not decrease the • Focus on high techniques threshold prices overly even they don’t win the and products with fewer competitor bid, they still have high market share and profit.

National Healthcare Security Administration Expend centralized procurement products • Increased number of centralized procurement products. Second procurement is 164 items, third is 355 items, and fourth is 215 items. • The main items of centralized procurement are hypolipidemics, antihypertensive, antithrombotic diabetes drugs. • The products will expend to orphan drug, shortage drug, Bio-similar drugs, and Chinese medicine.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

© 2021 SCPC, Ltd

Revenue Growth Strategy - Japan

==> picture [76 x 72] intentionally omitted <==

Collaboration Model Raw Material Strategy

 Strategic alliance with API manufacturer.

• CDMO

• Japan marketing partner

 API Vertical Integration with Syn-Tech.

• License Holder

Current State

On Going

• Obtained marketing licenses for Montelukast (Asthma) and Celecoxib (Anti-inflammatory)

• New business is continuing development.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

© 2021 SCPC, Ltd

Revenue Growth Strate – U.S.A. gy

==> picture [174 x 125] intentionally omitted <==

U.S.A. Market

• Largest Rx Market

• Characterized by lengthy review timelines and costly compilation and filing work

• SCP’s long term goals

Current Status

Strategy

• Strategic alliance with API manufacturer.

• Export of diabetic and amyotrophic lateral sclerosis(ALS) drugs

• treatment

• API Vertical Integration with Syn-Tech.

• Another approved drug, pending for patent expiration

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

22
----- End of picture text -----

© 2021 SCPC, Ltd

Future Operation Strategy

Future From Taiwan to International From Generics to BTG

2022

2021

USA、Japan

China

Core techniques and professional Global marketing 核心技術 skills to expend & 專業 海外市場操作 practices global sales turnover 借力使力

Increasing oversea Marketing revenue 增加海 外比例

• Enhance oversea sales’

 Foundation improvement  Create turnover rapidly  Pay attention to different countries marketing knowledge and business role

Mature R&D techniques to create turnover

resources

• Hire international

talents

 Seeking medium and long-term stability partnership cooperation

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

23
----- End of picture text -----

© 2021 SCPC, Ltd

The Greatest Honor with Drug Technology Develo ment Award in 2020 p

==> picture [233 x 350] intentionally omitted <==

• Antihypertensive drug- Co-Midis Tablet 80/5mg

• In 2020, SCP is honored with the only gold award as the greatest honor in manufacturing technology category.

 It is a compound made by Telmisartan 80mg and Amlodipine 5mg, mechanism of both two ingredients have complementary effect. It is not only use conveniently for doctors but also enhance patients drug compliance

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

24

© 2021 SCPC, Ltd

==> picture [261 x 540] intentionally omitted <==

----- Start of picture text -----

© 2021 SCPC, Ltd
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2020 Operating Results

 Further Operation Strategy  Corporate Social Responsibility (CSR)

25

Fan Dao Nan Foundation

Fan Dao Nan Foundation

==> picture [184 x 136] intentionally omitted <==

• Established in 1987

• Endowment Fund: NT$196 Million

 Annual Budget: NT$12 Million

==> picture [185 x 135] intentionally omitted <==

Principal Activities

• Non-profit education

• Cultural and educational

• Sponsor R&D and Innovation

development activities

• Scholarships and Talent Cultivation

==> picture [186 x 137] intentionally omitted <==

Rewards and Honors Received

 2011: Special Recognition Award – Dept. of Education

• 2012: Tainan City Govt. Grant for Scholarship Program

• 2013: National Special Selection Award for After-School Program – Dept. of Education

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

26
----- End of picture text -----

© 2021 SCPC, Ltd

Cor orate Social Res onsibilit in 2020 p p y

==> picture [51 x 52] intentionally omitted <==

==> picture [51 x 52] intentionally omitted <==

==> picture [51 x 51] intentionally omitted <==

Scholarships

Sunflower Wednesdays

Hope After-school Class

• University (related fields)::3university/4

• students

˙Weekday afternoons

˙Every Wednesday afternoons ， ˙4 Schools 243student Total scholarship NTD 400KK

• High school :7schools/ totaled 113 students

， ˙22 schools 1,780students

• Middle school:61schools/totaled 807 students

• Elementary school :237schools/totaled 2,760

• students

Total scholarship NTD 1.81MM

Total scholarship NTD 6.34 MM

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [52 x 51] intentionally omitted <==

Other Sponsorships

 Sponsorship to 11 non-forprofit organization for cultural and educational advancement

Grant Total- NTD 560KK

==> picture [52 x 51] intentionally omitted <==

Meal-Assistance

 In 2020, provided 4,553 meals to students during winter and summer vacation. Assisted Total- NTD270KK

==> picture [32 x 20] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [44 x 12] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [52 x 51] intentionally omitted <==

==> picture [51 x 52] intentionally omitted <==

Charity

 SCP Children’s Drawing

Competition  SCP National Table Tennis Q

 SCP National Table Tennis Competition* Prize Total – NT$250KK

27

© 2021 SCPC, Ltd

*Table tennis competition is suspended by COVID-19, budget 1.6MM

The Greatest Honor with Athletic Support Award in 2020

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

• Held the National Standard Cup of table tennis for 34 years straight.

• Provide a healthy competition environment for the players and train future

• professionals with the government.

• Encourage all of the Standard family to join in the charity work and participate in the

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

• Standard Cup.

• © 2021 SCPC, Ltd

28

Donated an Ambulance with the Battenburg Markings

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

• Battenburg usually promoted as high-visibility by busy street. Increase quality of emergency to rescue more injuries receive.

==> picture [64 x 63] intentionally omitted <==

Q

29

© 2021 SCPC, Ltd

The First Senior Gym in Taiwan – Athletic Trainin and Health Center g

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

• In 2020, the number of users is accumulated 127,580 user.

• Conducting healthy lectures that provide disease and healthcare knowledge. 2020 had conducted 14 lectures and had 228 participated.

==> picture [64 x 63] intentionally omitted <==

Q

• Conducting competition to encourage members muscular strength training.

30

© 2021 SCPC, Ltd

Free Bone Mass Measurement and Community Health Seminar

==> picture [214 x 172] intentionally omitted <==

• In 2020, 6 sessions of free bone mass measurement activity have been held and 500 people were measured.

• 5 sessions of community health lectures have been held, with a total of 700 participants.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

31

© 2021 SCPC, Ltd

==> picture [269 x 540] intentionally omitted <==

----- Start of picture text -----

© 2021 SCPC, Ltd
----- End of picture text -----

Q & A

==> picture [64 x 64] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

32